PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
56.81
ESG score 90-95% of Biotechnology median of 60.78. John Neff would demand higher returns to compensate for below-average ESG risk management.
51.50
Environmental score 90-95% of Biotechnology median of 56.96. John Neff would demand higher returns to compensate for below-average climate risk management.
59.27
Social score 90-95% of Biotechnology median of 64.13. John Neff would demand higher returns to compensate for below-average stakeholder management.
59.67
Governance score near Biotechnology median of 61.46. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.